Initial data from investigations of PCSK9 inhibition in humans indicate that PCSK9 inhibition may be a promising novel therapeutic alternative for the treatment of dyslipidemia and related cardiovascular diseases31,32. This evidence concerns the gene PCSK9 and metabolic syndrome.